Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,482.87 +4.97 (+0.09%) Dow
39,164.06 +36.26 (+0.09%) Nasdaq
17,858.68 +53.53 (+0.30%) Bitcoin USD
61,552.10 +783.09 (+1.29%) CMC Crypto 200
1,283.73 +17.58 (+1.39%)
TMCI Dec 2024 22.500 call
- GlobeNewswire
Treace to Present at Truist Securities MedTech Conference
Tuesday, June 18, 2024 at 8:00 am Eastern TimePONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside
- GuruFocus.com
Director Jane Kiernan Acquires 19,356 Shares of Treace Medical Concepts Inc (TMCI)
On May 14, 2024, Director Jane Kiernan purchased 19,356 shares of Treace Medical Concepts Inc (NASDAQ:TMCI), as reported in the SEC Filing.
- GuruFocus.com
Director Deepti Jain Acquires 25,000 Shares of Treace Medical Concepts Inc (TMCI)
On May 10, 2024, Deepti Jain, Director at Treace Medical Concepts Inc (NASDAQ:TMCI), purchased 25,000 shares of the company, as reported in a recent SEC Filing.
